Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opportunities to enhance cancer research through advocate-researcher partnerships.

Cancer research·2026
Same author

Recent Trends in Clinical Trials for Pediatric Sarcoma in the United States: An Analysis of ClinicalTrials.gov.

Children (Basel, Switzerland)·2026
Same author

Consensus recommendations in the management of jaw (gnathic) osteosarcoma.

Cancer·2026
Same author

Pulmonary Suffusion Refinements for Primary and Secondary Malignancies: Preliminary Analyses of Phase I Safety and Drug Delivery Data.

Cancers·2025
Same author

New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee.

Pediatric blood & cancer·2025
Same author

Advance Care Planning Conversations in Pediatric Patients with Refractory Oncologic Disease.

Children (Basel, Switzerland)·2025

Related Experiment Video

Updated: Mar 3, 2026

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

4.3K

CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond.

Jeremy Wells1, Ajay Gupta2,3

  • 1Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA. jwells2@buffalo.edu.

Cancer Metastasis Reviews
|March 2, 2026
PubMed
Summary

Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for pediatric solid tumors. Armored CAR-T cells are being investigated to overcome challenges in the tumor microenvironment and improve treatment efficacy.

Keywords:
CAR-TImmunotherapyPediatricSolidTumor

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

Related Experiment Videos

Last Updated: Mar 3, 2026

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

4.3K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • CAR-T cell therapy has revolutionized hematologic malignancy treatment.
  • Success in solid tumors is limited by the tumor microenvironment and CAR-T cell persistence.
  • Armored CAR-T cells offer a novel approach to enhance efficacy in solid tumors.

Purpose of the Study:

  • To review recent CAR-T cell therapy trials for pediatric solid malignancies.
  • To highlight the role and potential of armored CAR-T cells in this context.
  • To discuss challenges and ongoing developments in CAR-T cell therapy for pediatric solid tumors.

Main Methods:

  • Review of recent clinical trials and preclinical studies involving CAR-T cells for pediatric solid tumors.
  • Focus on armored CAR-T cell strategies and their application.
  • Analysis of factors affecting CAR-T cell efficacy in the tumor microenvironment.

Main Results:

  • CAR-T cells have FDA approval for six hematologic malignancies.
  • Early successes with armored CAR-T cells in pediatric solid tumors have been observed.
  • Targeting various tumor-associated antigens on pediatric solid tumors shows in vitro and in vivo promise.

Conclusions:

  • CAR-T cell therapy holds significant potential for treating pediatric solid tumors.
  • Armored CAR-T cells represent a promising strategy to overcome the hostile tumor microenvironment.
  • Ongoing research and innovative approaches are crucial for advancing CAR-T cell therapy in pediatric oncology.